Collegium Pharmaceutical Stock In The News

COLL Stock  USD 37.74  0.58  1.56%   
Our overall analysis of Collegium Pharmaceutical's news coverage and content from conventional and social sources shows investors' bearish mood towards Collegium Pharmaceutical. The specific impact of Collegium Pharmaceutical news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Collegium Pharmaceutical's overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Collegium Pharmaceutical headlines in addition to utilizing other, more conventional financial analysis modules. Check out Collegium Pharmaceutical Backtesting and Collegium Pharmaceutical Hype Analysis.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

Collegium Pharmaceutical Today Top News and Investor Outlook

Yahoo News
3 Profitable Stocks We Think Twice About
https://finance.yahoo.com/news/3-profitable-stocks-think-twice-135939704.html
 Bullish
Yahoo News
Arm initiated, Adobe downgraded: Wall Street's top analyst calls
https://finance.yahoo.com/news/arm-initiated-adobe-downgraded-wall-133303774.html
 Bullish
seekingalpha News
Collegium raises 2025 revenue guidance to $760M as Jornay PM growth accelerates
https://seekingalpha.com/news/4481665-collegium-raises-2025-revenue-guidance-to-760m-as-jornay-pm-growth-accelerates?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
nasdaq News
Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance
https://www.chartmill.com/news/COLL/Chartmill-32641-Collegium-Pharmaceutical-Inc-NASDAQCOLL-Reports-Record-Q2-2025-Earnings-and-Raises-Full-Year-Guidance
 Bullish
seekingalpha News
Collegium Pharmaceutical Non-GAAP EPS of $1.68 misses by $0.17, revenue of $188M beats by $7.12M
https://seekingalpha.com/news/4481244-collegium-pharmaceutical-non-gaap-eps-of-1_68-misses-by-0_17-revenue-of-188m-beats-by-7_12m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Neutral
Macroaxis News: globenewswire.com
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
https://www.globenewswire.com/news-release/2025/08/07/3129117/34897/en/Collegium-Reports-Second-Quarter-2025-Financial-Results-Raises-2025-Outlook.html
 Bullish
seekingalpha News
Here are the major earnings before the open Thursday
https://seekingalpha.com/news/4479885-here-are-the-major-earnings-before-the-open-thursday?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Neutral
Yahoo News
1 Cash-Producing Stock to Own for Decades and 2 We Ignore
https://finance.yahoo.com/news/1-cash-producing-stock-own-044124028.html
 Bullish
Yahoo News
Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks
https://finance.yahoo.com/news/unpacking-q1-earnings-organon-nyse-033457417.html
 Bullish
Yahoo News
1 Safe-and-Steady Stock to Keep an Eye On and 2 to Be Wary Of
https://finance.yahoo.com/news/1-safe-steady-stock-keep-043428713.html
 Bullish

Collegium Pharmaceutical Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Collegium and other traded companies coverage with news coverage. We help investors stay connected with Collegium headlines for the 17th of August 2025 to make an informed investment decision based on correlating the impacts of news items on Collegium Stock performance. Please note that trading solely based on the Collegium Pharmaceutical hype is not for everyone as timely availability and quick action are needed to avoid losses.
Collegium Pharmaceutical's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Collegium Pharmaceutical investors visualize upcoming and past events in order to time the market based on Collegium Pharmaceutical noise-free hype analysis.

Collegium Pharmaceutical Investors Sentiment

The influence of Collegium Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Collegium. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Collegium Pharmaceutical's public news can be used to forecast risks associated with an investment in Collegium. The trend in average sentiment can be used to explain how an investor holding Collegium can time the market purely based on public headlines and social activities around Collegium Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Collegium Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Collegium Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Collegium Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Collegium Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Collegium Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Collegium Pharmaceutical's short interest history, or implied volatility extrapolated from Collegium Pharmaceutical options trading.
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out Collegium Pharmaceutical Backtesting and Collegium Pharmaceutical Hype Analysis.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.34)
Earnings Share
1.06
Revenue Per Share
22.104
Quarterly Revenue Growth
0.294
Return On Assets
0.0776
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.